Published on : Apr 13, 2016
ALBANY, New York, April 13, 2016 – The report, titled “Global Ebola Partnering 2010 to 2016,” states the partnering deals and agreements entered into by the world’s leading healthcare companies to combat the deadly virus. The report is particularly helpful to prospective dealmakers who need to understand the research and development activities in the field, as well as the commercialization of technologies and products in the therapy area. The report offers valuable information through a partnering deals directory that categorizes the various deals among the healthcare companies in terms of valuation, type of deal, stage of development, and technology.
According to the World Health Organization (WHO), Ebola virus disease, earlier known as Ebola hemorrhagic fever, is a severe disease that can lead to death. The virus was first discovered in 1976. It is usually transmitted from wild animals and spreads through human population through human-to-human transmission. The average fatality rate of the disease is about as high as 50%. The first virus outbreak occurred across the remote villages in Central Africa that were in close proximity of tropical rainforests. However, the recent outbreak in West Africa in March 2014 included major urban and rural areas.
The Ebola virus disease is difficult to distinguish from other infectious diseases such as typhoid fever, malaria, and meningitis. The disease is usually diagnosed after performing various tests such as antigen-capture detection tests, ELISA, serum neutralization test, virus isolation by cell culture, RT-PCR assay, and electron microscopy. Preventive measures include reducing the risk of wildlife-to-human transmission, human-to-human transmission, and possible sexual transmission. Presently, there are no licensed Ebola vaccines. However, potential candidates are undergoing evaluation.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=677884
The report offers a holistic overview of the trends in the global Ebola partnering market during the period between 2010 and 2016, including a summary of deals on the basis of stages of development, technology, and deal type. A review of the top ten most active companies in the therapy area with comprehensive listing of the deals announced by each company has been included in the report.
The report also includes a comprehensive directory of partnering deals signed and announced by the major healthcare firms working on the development of Ebola vaccines since 2010. The directory is organized by company name, stage of development during signing of the deal, type of deal (co-promotion, licensing, and collaborative research and development), and technology. Each deal title links to an online version of the deal record, thereby providing an easy access to each contract document on demand. A summary of mergers and acquisitions deals, along with financings since 2010 have been provided in the report.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org